BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22492281)

  • 21. Impact of smoking status and pathologic type on epidermal growth factor receptor mutations in lung cancer.
    Huang YS; Yang JJ; Zhang XC; Yang XN; Huang YJ; Xu CR; Zhou Q; Wang Z; Su J; Wu YL
    Chin Med J (Engl); 2011 Aug; 124(16):2457-60. PubMed ID: 21933587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
    Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; Mitsudomi T
    Cancer Res; 2004 Dec; 64(24):8919-23. PubMed ID: 15604253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
    Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ
    Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Epidermal growth factor receptor gene mutations, amplification and clinicopathologic correlation in patients with lung cancer].
    Zhang J; Wu J; Gao H; Zhu L; Shao JC; Shi MP; Han BH
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):675-8. PubMed ID: 22321546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor mutations in lung adenocarcinoma in Malaysian patients.
    Liam CK; Wahid MI; Rajadurai P; Cheah YK; Ng TS
    J Thorac Oncol; 2013 Jun; 8(6):766-72. PubMed ID: 23575413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.
    Ohba T; Toyokawa G; Osoegawa A; Hirai F; Yamaguchi M; Taguchi K; Seto T; Takenoyama M; Ichinose Y; Sugio K
    Surg Today; 2016 Sep; 46(9):1091-8. PubMed ID: 26711128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinoma.
    Fujimoto D; Tomii K; Otoshi T; Kawamura T; Tamai K; Takeshita J; Tanaka K; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Hata A; Tachikawa R; Otsuka K; Hamakawa H; Katakami N; Takahashi Y; Imai Y
    Lung Cancer; 2013 May; 80(2):159-64. PubMed ID: 23419507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.
    Lin MW; Wu CT; Shih JY; Chang YL; Yang PC
    J Surg Oncol; 2014 Aug; 110(2):99-106. PubMed ID: 24788590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The association between tumor epidermal growth factor receptor (EGFR) mutation and multiple primary malignancies in patients with adenocarcinoma of the lungs.
    Luo YH; Ho HL; Tsai CM; Shih JF; Chiu CH; Lai SL; Lee YC; Perng RP; Whang-Peng J; Chou TY; Chen YM
    Am J Clin Oncol; 2015 Apr; 38(2):147-51. PubMed ID: 23608835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations.
    Hiramatsu M; Ninomiya H; Inamura K; Nomura K; Takeuchi K; Satoh Y; Okumura S; Nakagawa K; Yamori T; Matsuura M; Morikawa T; Ishikawa Y
    Lung Cancer; 2010 Oct; 70(1):94-102. PubMed ID: 20117855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiogenomic correlation in lung adenocarcinoma with epidermal growth factor receptor mutations: Imaging features and histological subtypes.
    Hong SJ; Kim TJ; Choi YW; Park JS; Chung JH; Lee KW
    Eur Radiol; 2016 Oct; 26(10):3660-8. PubMed ID: 26787602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
    Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
    Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I Lung Adenocarcinoma.
    Isaka T; Yokose T; Ito H; Nagata M; Furumoto H; Nishii T; Katayama K; Yamada K; Nakayama H; Masuda M
    Medicine (Baltimore); 2015 Oct; 94(42):e1784. PubMed ID: 26496308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Relationship between histopathologic characteristics and epidermal growth factor receptor mutation in lung adenocarcinoma].
    Wang K; Gong H; Li X; Yang Z; Cao P; Wand C; Jiang Y; Wang H; Wang Y; Zhang G
    Zhonghua Bing Li Xue Za Zhi; 2015 Mar; 44(3):170-4. PubMed ID: 26268750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CT Features Associated with Epidermal Growth Factor Receptor Mutation Status in Patients with Lung Adenocarcinoma.
    Liu Y; Kim J; Qu F; Liu S; Wang H; Balagurunathan Y; Ye Z; Gillies RJ
    Radiology; 2016 Jul; 280(1):271-80. PubMed ID: 26937803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR exon 19 in-frame deletion and polymorphisms of DNA repair genes in never-smoking female lung adenocarcinoma patients.
    Yang SY; Yang TY; Li YJ; Chen KC; Liao KM; Hsu KH; Tsai CR; Chen CY; Hsu CP; Hsia JY; Chuang CY; Tsai YH; Chen KY; Huang MS; Su WC; Chen YM; Hsiung CA; Shen CY; Chang GC; Yang PC; Chen CJ
    Int J Cancer; 2013 Jan; 132(2):449-58. PubMed ID: 22573488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.
    Villa C; Cagle PT; Johnson M; Patel JD; Yeldandi AV; Raj R; DeCamp MM; Raparia K
    Arch Pathol Lab Med; 2014 Oct; 138(10):1353-7. PubMed ID: 24571650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic phenotype of stage IV lung adenocarcinoma: relationship with epidermal growth factor receptor mutation.
    Lee EY; Khong PL; Lee VH; Qian W; Yu X; Wong MP
    Clin Nucl Med; 2015 Mar; 40(3):e190-5. PubMed ID: 25608155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis.
    Boldrini L; Gisfredi S; Ursino S; Camacci T; Baldini E; Melfi F; Fontanini G
    J Thorac Oncol; 2007 Dec; 2(12):1086-90. PubMed ID: 18090579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.